Fulcrum Therapeutics, a company engaged in discovery and development of small molecule therapies for the treatment of serious genetic diseases, has raised $80m in a Series B funding round.
German pharma company Boehringer Ingelheim has announced a collaboration with Tsinghua University in Beijing to research and develop immunological therapies for infectious diseases.
CHDI Foundation has extended its collaboration with Evotec through to 2023 to fight against Huntington's disease, a familial disease caused by a mutation in the huntingtin gene.
IXICO, the data science company offering insights in neuroscience, has signed a further change order to a current contract which increases the total contract value to €1.3m.
KaNDy Therapeutics, a UK-based clinical stage company focused on women’s health, has raised £25m in a Series C financing round.
Roche Group’s member Genentech has collaborated with Affimed for the development and commercialization of NK cell engager-based immunotherapeutics for multiple cancer targets.
Biopharmaceutical company Harbour BioMed has secured $85m series B financing to advance the growth of its therapeutic pipeline, including both clinical and discovery stage programs.
South Korea-based JW Pharmaceutical (JWP) has entered into a global licensing agreement with LEO Pharma whereby the former will grant the latter's exclusive rights to develop and commercialize its atopic dermatitis drug JW1601 in a deal that could reach KRW450bn ($402m).
bluebird bio and Gritstone Oncology have partnered to research, develop and commercialize products for the treatment of cancer using cell therapy.
ApoGen Biotechnologies, a biotechnology firm engaged in the development of a new class of therapeutics targeting drivers of cancer genomic mutations, has expanded its series A financing to a total of $11m.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.